Join the Vyvanse group to help and get support from people like you.
Vyvanse News
ADHD Patients Could Face Disrupted Access to Meds Following Fraud Case
FRIDAY, June 14, 2024 – The two top officers of a telehealth company that began to distribute ADHD drugs widely during the pandemic have been charged with health care fraud, the U.S. Department of...
Seniors With ADHD Face Higher Car Crash Risk
WEDNESDAY, Oct. 4, 2023 – While studies of ADHD and driving usually target teens, a new one focused on seniors found they have a significantly higher risk of car crashes. Older adults with...
ADHD: What Parents Need to Know
MONDAY, Sept. 4, 2023 – Lots of children and adolescents have the condition known as ADHD, or attention-deficit/hyperactivity disorder. What should parents know? A number of treatments exist to help...
Counterfeit Pills Fuel Rising Number of Fatal Drug Overdoses
FRIDAY, Sept. 1, 2023 – A growing number of overdose deaths in the United States involve counterfeit pills, health officials reported Thursday. Overdose deaths involving counterfeit pills were twice...
Output of ADHD Meds Needs Boosting
WEDNESDAY, Aug. 2, 2023 – While demand for prescription stimulants is surging, a shortage of the drugs persists, so federal officials have stepped in and asked drug companies to ramp up production...
FDA Expands Uses of Vyvanse to Treat Binge-Eating Disorder
January 30, 2015 – The U.S. Food and Drug Administration today expanded the approved uses of Vyvanse (lisdexamfetamine dimesylate) to treat binge-eating disorder in adults. The drug is the first...
Vyvanse (lisdexamfetamine dimesylate) Capsules, (CII) Now Approved in the US for Maintenance Treatment in Adults with ADHD
PHILADELPHIA, February 7, 2012 /PRNewswire/ – Vyvanse (lisdexamfetamine dimesylate), an approved treatment for Attention-Deficit/Hyperactivity Disorder (ADHD) in patients ages 6 and above, is the...
FDA Approves Vyvanse (lisdexamfetamine dimesylate) Capsules CII for the Treatment of ADHD in Adolescents
PHILADELPHIA - November 15, 2010 Shire plc, the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) approved the prescription medication Vyvanse...
FDA Medwatch Alert: Stimulant Medications used in Children with Attention-Deficit/Hyperactivity Disorder - Communication about an Ongoing Safety Review
Products involved include: Focalin, Focalin XR (dexmethylphenidate HCl ); Dexedrine, Dexedrine Spansules, Dextroamphetamine ER, Dextrostat (dextroamphetamine sulfate); Vyvanse (lisdexamfetamine...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Binge Eating Disorder, Attention-Deficit Hyperactivity Disorder (ADHD)